Relation of pulmonary responses induced by 6.6-h exposures to 0.08 ppm ozone and 2-h exposures to 0.30 ppm ozone via chamber and face-mask inhalation.
While direct comparison of pulmonary responses to 6.6-h exposures to 0.08 to 0.12 ppm ozone O3 have demonstrated that chamber and face-mask inhalation methods yield closely similar results, no comparative study of responses to 2-h intermittent exercise (IE) exposures to higher O3 concentrations have been reported. The present study was designed to achieve three primary objectives: (1) to compare pulmonary function and symptoms effects of a 2-h IE exposure to 0.30 ppm O3 via chamber and via face mask; (2) to compare the pulmonary effects of 6.6-h chamber exposure to 0.08 ppm O3 to those observed in 2-h IE 0.30 ppm O3 exposures via chamber and via face mask; and (3) to examine filtered air (FA) recovery pulmonary and symptoms responses following chamber exposures of 6.6 h to 0.08 ppm O3 and 2 h to 0.30 ppm O3. A simple regression of postexposure percent change in FEV(1.0) for the 2-h IE, 0.30-ppm O3 chamber exposure as a function of postexposure percent change in FEV(1.0) for the 2-h IE, 0.30-ppm O3 exposure with face mask yielded an R(2) of 0.83. Further, a regression of the postexposure FEV(1.0) response to the chamber 6.6-h, 0.08-ppm O3 exposure as a function of postexposure FEV(1.0) response to the face mask 2-h IE, 0.30-ppm O3 exposure (R(2) of 0.34) was similar to the 0.40 value obtained for the two chamber exposures FEV(1.0) response comparison. Results of the 1.4-h FA recovery following the two chamber O3 exposures showed different rates of FEV(1.0) and symptoms rectification that appeared related to the total O3 dose (product of O3 concentration, ventilation rate, and duration). More data are needed to clarify short-term recovery of O3-induced pulmonary effects and how they may be related to the more abundant data available on the delayed recovery of pulmonary function seen over longer time periods, such as 24 h.
Adams
William C
WC
Human Performance Laboratory, University of California, Davis, CA 95616, USA. wcadams@ucdavis.edu
D000280:Administration, Inhalation; D000293:Adolescent; D000328:Adult; D000388:Air / Q000032:analysis*; D001273:Atmosphere Exposure Chambers / Q000706:statistics & numerical data*; D003371:Cough / Q000503:physiopathology; D004417:Dyspnea / Q000503:physiopathology; D005080:Exercise Test; D005260:Female; D005374:Filtration / Q000295:instrumentation; D006801:Humans; D007320:Inspiratory Capacity / Q000187:drug effects / Q000502:physiology; D008297:Male; D008851:Micropore Filters; D010126:Ozone / Q000008:administration & dosage* / Q000009:adverse effects* / Q000032:analysis; D010146:Pain / Q000503:physiopathology; D020127:Recovery of Function; D012129:Respiratory Function Tests / Q000379:methods*; D012134:Respiratory Protective Devices / Q000706:statistics & numerical data*; D013147:Spirometry / Q000706:statistics & numerical data; D013997:Time Factors
D010126:Ozone